התחל במצב לא מקוון עם האפליקציה Player FM !
S2/E112. What's Coming in Obesity Medicine? The Med Pipeline with Dr. Sean Wharton
Manage episode 422869155 series 3450393
What new medications are coming down the pipeline in Obesity Medicine? I explore the latest and greatest in obesity pharmacotherapy with my guest today, Dr. Sean Wharton.
Dr. Wharton is one of the leading Canadian researchers in Obesity Medicine. He is co-lead author of the Canadian Obesity Guidelines and the primary author of many of the clinical trials in bariatric medicine and type 2 diabetes. We discussed what is being studied in Phase 2 and 3 clinical trials in obesity management including:
- Semaglutide (Wegovy/Ozempic)
- Tirzepatide (Mounjaro/Zepbound)
- Retatrutide (GLP1, GIP, glucagon triple analogue)
- Cagrisema (amylin/GLP1 dual analogue)
- Bimagrumab (human monoclonal antibody)
- Cannabinoid-receptor antagonists (CB1)
- Orforglipron
- Oral GLP1 peptides
- Medications taken once monthly
**A small error that Dr. Wharton wanted to correct. The Amgen molecule discussed today is a GIPR antagonist, not a glucagon antagonist.
This week’s show brought to you by FRIDAY’S HEALTH.
If you’re in the USA looking for a healthcare provider and comprehensive obesity medicine program to support you in a science-backed, compassionate way, then check out Fridays Health. Each patient works with a medical provider as well as a team of coaches to pair medical treatment with effective behavioural support. Use code HIGH to get $20 USD off the first month of your membership.
FIND DR. SEAN WHARTON
Instagram @drseanwharton
Clinical Trials https://whartonmedicalclinic.com/clinical-trials/
FOLLOW SASHA
Instagram - https://www.instagram.com/sashahighmd/
Tiktok - https://www.tiktok.com/@sashahighmd
WORK WITH ME
Join my Weight Loss Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweight
Recover Strong for Binge Eating - https://www.sashahighmd.com/bed
Ontario OHIP-covered Obesity Medicine https://www.highmetabolicclinic.com
124 פרקים
Manage episode 422869155 series 3450393
What new medications are coming down the pipeline in Obesity Medicine? I explore the latest and greatest in obesity pharmacotherapy with my guest today, Dr. Sean Wharton.
Dr. Wharton is one of the leading Canadian researchers in Obesity Medicine. He is co-lead author of the Canadian Obesity Guidelines and the primary author of many of the clinical trials in bariatric medicine and type 2 diabetes. We discussed what is being studied in Phase 2 and 3 clinical trials in obesity management including:
- Semaglutide (Wegovy/Ozempic)
- Tirzepatide (Mounjaro/Zepbound)
- Retatrutide (GLP1, GIP, glucagon triple analogue)
- Cagrisema (amylin/GLP1 dual analogue)
- Bimagrumab (human monoclonal antibody)
- Cannabinoid-receptor antagonists (CB1)
- Orforglipron
- Oral GLP1 peptides
- Medications taken once monthly
**A small error that Dr. Wharton wanted to correct. The Amgen molecule discussed today is a GIPR antagonist, not a glucagon antagonist.
This week’s show brought to you by FRIDAY’S HEALTH.
If you’re in the USA looking for a healthcare provider and comprehensive obesity medicine program to support you in a science-backed, compassionate way, then check out Fridays Health. Each patient works with a medical provider as well as a team of coaches to pair medical treatment with effective behavioural support. Use code HIGH to get $20 USD off the first month of your membership.
FIND DR. SEAN WHARTON
Instagram @drseanwharton
Clinical Trials https://whartonmedicalclinic.com/clinical-trials/
FOLLOW SASHA
Instagram - https://www.instagram.com/sashahighmd/
Tiktok - https://www.tiktok.com/@sashahighmd
WORK WITH ME
Join my Weight Loss Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweight
Recover Strong for Binge Eating - https://www.sashahighmd.com/bed
Ontario OHIP-covered Obesity Medicine https://www.highmetabolicclinic.com
124 פרקים
כל הפרקים
×ברוכים הבאים אל Player FM!
Player FM סורק את האינטרנט עבור פודקאסטים באיכות גבוהה בשבילכם כדי שתהנו מהם כרגע. זה יישום הפודקאסט הטוב ביותר והוא עובד על אנדרואיד, iPhone ואינטרנט. הירשמו לסנכרון מנויים במכשירים שונים.